Unia Europejska - estoński - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastilised ained - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Unia Europejska - estoński - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vaktsiinid - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 ja 5. 1 in product information document). kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Unia Europejska - estoński - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaktsiinid - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Unia Europejska - estoński - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaktsiinid - active immunisation against h5 subtype of influenza a virus.

Estonia - estoński - Ravimiamet

octapharma (ip) - immunoglobuliin, ekstravaskulaarseks kasutamiseks - süstelahus - 165mg 1ml 10ml 1tk; 165mg 1ml 24ml 1tk; 165mg 1ml 6ml 10tk; 165mg 1ml 24ml 10tk; 165mg 1ml 48ml 20tk; 165mg 1ml 48ml 1tk; 165mg 1ml 20ml 10tk; 165mg 1ml 12ml 1tk; 165mg 1ml 10ml 10tk; 165mg 1ml 10ml 20tk; 165mg 1ml 6ml 1tk; 165mg 1ml 20ml 20tk; 165mg 1ml 20ml 1tk; 165mg 1ml 12ml 20tk; 165mg 1ml 6ml 20tk; 165mg 1ml 24ml 20tk

Estonia - estoński - Ravimiamet

baxalta innovations gmbh - faktor viii inhibiitorist möödamineva aktiivsusega hüübimisfaktorid - infusioonilahuse pulber ja lahusti - 50ühik 1ml 20ml 1tk; 50ühik 1ml 50ml 1tk; 50ühik 1ml 10ml 1tk

Estonia - estoński - Ravimiamet

baxalta innovations gmbh - faktor viii inhibiitorist möödamineva aktiivsusega hüübimisfaktorid - infusioonilahuse pulber ja lahusti - 25ühik 1ml 20ml 1tk

Estonia - estoński - Ravimiamet

baxalta innovations gmbh - faktor viii inhibiitorist möödamineva aktiivsusega hüübimisfaktorid - infusioonilahuse pulber ja lahusti - 100ühik 1ml 25ml 1tk; 100ühik 1ml 10ml 1tk; 100ühik 1ml 5ml 1tk

Estonia - estoński - Ravimiamet

fresenius kabi polska sp. z o.o. - želatiin (veevaba)+naatriumkloriid+kaaliumkloriid+magneesiumkloriid+naatriumlaktaat - infusioonilahus - 30mg+5,382mg+0,373mg+0,305mg+3,36mg 1ml 500ml 1tk

Estonia - estoński - Ravimiamet

hospira uk limited - tsefepiim - süste-/infusioonilahuse pulber - 2g 20ml 5tk; 2g 20ml 10tk; 2g 20ml 1tk